Compare CRWS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRWS | NEUP |
|---|---|---|
| Founded | 1957 | 1996 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Textiles | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 23.0M |
| IPO Year | 1994 | N/A |
| Metric | CRWS | NEUP |
|---|---|---|
| Price | $2.73 | $4.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 24.9K | ★ 54.3K |
| Earning Date | 02-11-2026 | 02-17-2026 |
| Dividend Yield | ★ 12.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.51 | N/A |
| 52 Week Low | $2.35 | $3.65 |
| 52 Week High | $3.88 | $21.31 |
| Indicator | CRWS | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 55.35 |
| Support Level | $2.54 | $3.92 |
| Resistance Level | $2.94 | $5.06 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 26.58 | 42.80 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.